Outcome of metastatic melanoma following immune checkpoint inhibitor treatment by tumor infiltrating lymphocyte of primary cutaneous site.

• DOI: 10.1200/jco.2020.38.15_suppl.e22005
• Publication Date: 2020-05-25T15:45:50Z
• Authors: Upendra P. Hegde; Aaron N. Holmes; Christina Elizabe...; Sophie Masternak; Cucka Bethany
• Keywords: Tumor-infiltrating lymphocytes

e22005 Background: TIL include antigen specific clonal T cells responding to tumor antigens (TA) in the microenvironment. Biological relevance of at PCM following ICI treatment MM is not clear. Since there overlap TA between primary and its metastasis, we hypothesized that site may serve as a biomarker response MM. Methods: We did retrospective analysis patients (pts.) receiving 2012 2019 an IRB approved protocol. Response survival 12, 24 36 months (mths) was correlated with TIL. Pts. who received least one dose for were eligible those metastasis from unknown PCM, anti-BRAF or lacked information on excluded. stratified group (gr.) A, B C representing brisk, non-brisk absent respectively. Responses defined by RECIST criteria (response, no response, stable disease) well overall calculated time initiation death any cause (OS) mths PCM. Results: 42 pts. 2012-2019 meeting eligibility criteria. Median age 68 years (yrs.) (63, 71 73 yr. respectively C), 27 male, 15 women. The median thickness 3.5, 3.75 4.75 mm 11 14, 9 16 O 12 responded while 2, 5, 14 1,2, 0 showed disease O.S. 24, mths. 12/14, 11/16 1/12 pts.; 10/14, 7/16, 0/12 8/14, 6/16 three groups. Conclusions: Brisk favorable unfavorable intermediate outcomes. Larger data set could help validate our findings.